Tag: Mirikizumab

Improving efficacy with longer mirikizumab treatment in CD

Presented By
Prof. Séverine Vermeire, KU Leuven, Belgium
Trial
Phase 3, VIVID-2
Conference
ECCO 2025
Type
Peer-reviewed article

8 April 2025 10:39

Meaningful corticosteroid-sparing effect of mirikizumab in UC

Presented By
Prof. David Laharie, University of Bordeaux, France
Trial
Phase 3, LUCENT-2
Conference
UEGW 2024
Type
Peer-reviewed article

28 November 2024 11:22

VIVID-1: Mirikizumab meets expectations in Crohn’s disease

Presented By
Prof. Marc Ferrante, University Hospitals Leuven, Belgium
Trial
Phase 3, VIVID-1
Conference
ECCO 2024
Type
Peer-reviewed article

18 April 2024 13:49

Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease

Presented By
Prof. Simon Travis, University of Oxford, UK
Trial
Phase 3, VIVID-1
Conference
ECCO 2024
Type
Peer-reviewed article

18 April 2024 13:41

LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history

Presented By
Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy
Trial
Phase 3, LUCENT-2
Conference
UEGW 2023
Type
Peer-reviewed article

7 December 2023 15:23

Ulcerative colitis: bowel urgency remission associated with improvement in fatigue

Presented By
Dr David Rubin, University of Chicago, IL, USA
Trial
Phase 3, LUCENT-1, LUCENT-2
Conference
DDW 2023
Type
News article

13 June 2023 13:52

Maintained symptom control with mirikizumab in UC

Presented By
Prof. Axel Dignass, Agaplesion Markus Hospital, Germany
Trial
Phase 3, LUCENT 2
Conference
UEGW 2022
Type
Peer-reviewed article

1 December 2022 21:49

Mirikizumab successfully resolves active histologic inflammation in UC

Presented By
Prof. Fernando Magro, CHU de SĂŁo JoĂŁo, Portugal
Trial
Phase 2, LUCENT 2
Conference
UEGW 2022
Type
Peer-reviewed article

1 December 2022 21:44

IL-23 inhibition beneficial in maintenance treatment of UC

Presented By
Prof. Marla C. Dubinsky, Icahn School of Medicine at Mount Sinai, NY, USA
Trial
Phase 3, LUCENT-2
Conference
DDW 2022
Type
News article

14 June 2022 22:01

Mirikizumab efficacious for active ulcerative colitis

Presented By
Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands
Trial
Phase 3, LUCENT-1
Conference
ECCO 2022
Type
Peer-reviewed article

12 April 2022 16:18

ECCO 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ECCO 2022

8 March 2022 10:18

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By
Dr Kim Papp, Probity Medical Research, Canada
Trial
Phase 3, OASIS-2
Conference
EADV 2020
Type
Peer-reviewed article

17 December 2020 13:44

Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease

Principal Investigator
Prof. Bruce E. Sands, Icahn School of Medicine at Mount Sinai, NY, USA
Trial
Phase 2, SERENITY
Conference
UEGW 2020
Type
News article

2 November 2020 12:20

Phase 2 data shows benefit for mirikizumab in CD patients

Presented By
Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, New York, USA
Conference
UEGW 2019
Type
Peer-reviewed article

23 October 2019 19:42

p19-Directed IL-23 antibody mirikizumab

Conference
ECCO 2019
Type
Peer-reviewed article

9 May 2019 19:26
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com